HomeCompareSPHRF vs FCPT

SPHRF vs FCPT: Dividend Comparison 2026

SPHRF yields 606.06% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRF wins by $280371.12M in total portfolio value
10 years
SPHRF
SPHRF
● Live price
606.06%
Share price
$0.33
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$280371.17M
Annual income
$211,667,981,687.60
Full SPHRF calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — SPHRF vs FCPT

📍 SPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRFFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRF + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHRF pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRF
Annual income on $10K today (after 15% tax)
$51,515.15/yr
After 10yr DRIP, annual income (after tax)
$179,917,784,434.46/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, SPHRF beats the other by $179,917,779,525.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRF + FCPT for your $10,000?

SPHRF: 50%FCPT: 50%
100% FCPT50/50100% SPHRF
Portfolio after 10yr
$140185.61M
Annual income
$105,833,993,731.44/yr
Blended yield
75.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

SPHRF
No analyst data
Altman Z
11.2
Piotroski
3/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRF buys
0
FCPT buys
0
No recent congressional trades found for SPHRF or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRFFCPT
Forward yield606.06%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$280371.17M$49.1K
Annual income after 10y$211,667,981,687.60$5,775.28
Total dividends collected$274648.71M$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: SPHRF vs FCPT ($10,000, DRIP)

YearSPHRF PortfolioSPHRF Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$71,306$60,606.06$11,401$700.92+$59.9KSPHRF
2$480,183$403,885.93$13,064$864.84+$467.1KSPHRF
3$3,055,680$2,541,883.57$15,051$1,072.48+$3.04MSPHRF
4$18,386,820$15,117,242.14$17,442$1,337.22+$18.37MSPHRF
5$104,687,331$85,013,433.96$20,340$1,677.08+$104.67MSPHRF
6$564,382,839$452,367,394.46$23,880$2,116.57+$564.36MSPHRF
7$2,883,114,581$2,279,224,943.60$28,241$2,689.36+$2883.09MSPHRF
8$13,966,501,456$10,881,568,854.67$33,660$3,442.07+$13966.47MSPHRF
9$64,208,586,900$49,264,430,341.75$40,456$4,439.95+$64208.55MSPHRF
10$280,371,169,670$211,667,981,687.60$49,063$5,775.28+$280371.12MSPHRF

SPHRF vs FCPT: Complete Analysis 2026

SPHRFStock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRF Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this SPHRF vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRF vs SCHDSPHRF vs JEPISPHRF vs OSPHRF vs KOSPHRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.